# A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4

Source: https://onco.cc/trials/nct04274738/  
OnCo record `nct04274738` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of Mavorixafor and Ibrutinib in Waldenström macroglobulinaemia, run by X4 Pharmaceuticals, completed.

## Summary

A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4 is a phase 1 interventional study registered as NCT04274738 by X4 Pharmaceuticals, with 16 participants recorded, started 2020-04-30 and reaching its primary completion in 2022-10-31. Interventions recorded: Mavorixafor, Ibrutinib. Conditions recorded: Waldenstrom's Macroglobulinemia.

Linked to the drug Mavorixafor because the registry names it among its interventions and Waldenström macroglobulinaemia among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04274738
- Phase: 1
- Setting: A Phase 1b Trial of Mavorixafor, an Oral CXCR4 Antagonist, in Combination With Ibrutinib in Patients With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4
- Sponsor: X4 Pharmaceuticals
- Enrolled: 16

## Sources

- ClinicalTrials.gov NCT04274738: https://clinicaltrials.gov/study/NCT04274738

## Connected records

- cancers: [Waldenström macroglobulinaemia](https://onco.cc/cancers/waldenstrom/)
- drugs: [Ibrutinib](https://onco.cc/drugs/ibrutinib/), [Mavorixafor](https://onco.cc/drugs/mavorixafor/)
- companies: [X4 Pharmaceuticals](https://onco.cc/companies/x4-pharmaceuticals/)

---
JSON: https://onco.cc/api/v1/entities/nct04274738.json